Mouse IFN-γ ELISA Kit

lMagnetically navigated M-BiNanoAb-engineered AR-T-mimicking cells improved therapeutic efficacy against the Bl6-F10 tumor model. (a) Schematic illustrating the treatment procedure for the B16 F10 melanoma. (b,c) Average (b) and individual (c) tumor growth curves of B16-F10 tumors in different groups (n = 7). (d) Digital photographs of the colle cted tumor masses at the treatment endpoint (n = 7). (e) The number ofinfiltrating CD8+ T cells in tumor tissues of each group after treatment (n = 5). `) Immunofluorescence staining of the tissue sections to analyze tumor-infiltrated CD8+ and CD69+ T cells. Representative images out of five images ol tained are shown (n=5). (g,h) Representative flow cytometry analysis of CD8+(g and CD69+ CD8+ (h)T cells percentages in corresponding parental opulation. (i,j) Quantitative analysis showing the average proportions of CD8* (i) sA analysis of the IFN-y(k), TNF-a (l) levels in tumor tissue after administration of and CD69+CD8+(j)T cells in B16-F10 tumor tissues(n= 5).(k,l)ELI verage proportions of PD1+ CD8+ (m), TIM3+ CD8+ (n), Foxp3+ CD4* (o), TCF1+ various treatments (n =5).m-g)Quantitative analysis showing the a CD8+(p), and Ki67+ CD8+(q)T cell subsets in corresponding parenta population (n= 5). Quantitative data are presented as means + standard deviation )5, with significance levels denoted as follows: n.s. (not significant, p > 0.05), *p< (s.d.). Statistical significance was determined at a threshold of p < 0. 0.05,**p < 0.01,***p <0.00l, and ****p<0.0001.P values are shown in graphs and were determined using one-way analysis of variance (Figure 5e,i-g and two-way analysis of variance (Figure 5b)